Jon Marc Wigginton Net Worth

The estimated Net Worth of Jon Marc Wigginton is at least $585 Thousand dollars as of 16 January 2018. Jon Wigginton owns over 5,000 units of Cullinan Oncology stock worth over $584,782 and over the last 10 years Jon sold CGEM stock worth over $0.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Jon Wigginton CGEM stock SEC Form 4 insiders trading

Jon has made over 16 trades of the Cullinan Oncology stock since 2014, according to the Form 4 filled with the SEC. Most recently Jon exercised 5,000 units of CGEM stock worth $23,500 on 16 January 2018.

The largest trade Jon's ever made was exercising 20,000 units of Cullinan Oncology stock on 1 August 2016 worth over $94,000. On average, Jon trades about 3,788 units every 38 days since 2014. As of 16 January 2018 Jon still owns at least 32,524 units of Cullinan Oncology stock.

You can see the complete history of Jon Wigginton stock trades at the bottom of the page.

What's Jon Wigginton's mailing address?

Jon's mailing address filed with the SEC is C/O SUTRO BIOPHARMA, INC., 111 OYSTER POINT BLVD., SOUTH SAN FRANCISCO, CA, 94080.

Insiders trading at Cullinan Oncology

Over the last 4 years, insiders at Cullinan Oncology have traded over $29,405,190 worth of Cullinan Oncology stock and bought 2,950,136 units worth $38,299,215 . The most active insiders traders include Partners L P/Ilbiotechnolog..., Ansbert Gadicke, and Morana Jovan Embiricos. On average, Cullinan Oncology executives and independent directors trade stock every 14 days with the average trade being worth of $914,589. The most recent stock trade was executed by Jennifer Michaelson on 5 September 2024, trading 8,000 units of CGEM stock currently worth $144,720.

What does Cullinan Oncology do?

Cullinan Oncology Inc., a biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States. The company's lead candidate is the CLN-081, an orally available small molecule that is in a Phase I/IIa dose escalation and expansion trial for treating patients with non-small cell lung cancer. Its preclinical products include CLN-049, a humanized bispecific antibody for the treatment of acute myeloid leukemia; CLN-619, a monoclonal antibody for the treatment of solid tumors; CLN-617, a fusion protein for the treatment of solid tumors; CLN-978, a T cell engaging antibody for B-cell malignancies; Opal, a bispecific fusion protein to block the PD-1 axis, and to activate the 4-IBB/CD137 pathway on T cells in tumors; and Jade, a cell therapy to target a novel senescence and cancer-related protein. The company has collaboration agreements with Cullinan Pearl Corp. to develop, manufacture, and commercialize CLN-081 and products containing CLN-081; and Adimab, LLC to discover and/or optimize antibodies. Cullinan Oncology, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.

Complete history of Jon Wigginton stock trades at Macrogenics Inc, Sutro Biopharma Inc, Checkmate Pharmaceuticals, and Cullinan Oncology

Cullinan Oncology executives and stock owners

Cullinan Oncology executives and other stock owners filed with the SEC include:

• Dr. Patrick A. Baeuerle Ph.D.,
  Co-Founder & Acting Chief Scientific Officer of Biologics
• Owen P. Hughes Jr.,
  Strategic Advisor
• Dr. Jeffrey Jones M.B.A., M.D., M.P.H.,
  Chief Medical Officer
• Steve Andre,
  Chief HR Officer
• Rose Weldon,
  VP of Communications
• Kerry Whalen,
  Sr. Director of Preclinical & Early Devel.
• Dr. Jennifer Michaelson Ph.D.,
  Chief Devel. Officer of Biologics
• Leigh Zawel Ph.D.,
  Chief Scientific Officer of Small Molecules
• Corinne Savill Ph.D.,
  Acting Chief Bus. Officer
• Raymond T. Keane,
  Chief Legal Officer & Sec.
• Nate Nguyen,
  Director of Accounting & Controller
• Jeffrey Trigilio,
  CFO & Treasurer
• Nadim Ahmed,
  Pres, CEO & Director
• Vision Scs Jovan Embiricos ...,
  
• Anthony Rosenberg,
  
• Morana Jovan Embiricos,
  10% owner
• Jacquelyn L Sumer,
  Chief Legal Officer
• Nadim Ahmed,
  President and CEO
• Raymond T Keane,
  Chief Legal Officer
• Jon Marc Wigginton,
  Chief Medical Officer
• Owen Hughes,
  President and CEO
• Leigh Zawel,
  See Remarks
• Morana Globeways Holdings L...,
  
• Ansbert Gadicke,
  Director
• Oncology Impact Fund L.P.On...,
  
• Oncology Impact Fund L.P.On...,
  
• Partners L P/Ilbiotechnolog...,
  
• Jennifer Michaelson,
  Chief Scientific Officer
• David P. Ryan,
  
• Patrick Baeuerle,
  Chief Scientific Officer
• Bioscience I 2017 Ltd Jovan...,
  
• Stephen W Webster,
  
• Thomas Ebeling,
  
• Anne Marie Martin,
  
• Jeffrey Trigilio,
  Chief Financial Officer
• Jeffrey Alan Jones,
  Chief Medical Officer
• Corrine Savill,
  Chief Business Officer
• Mary Kay Fenton,
  Chief Financial Officer
• David D. Meek,
  
• Mary Thistle,